Literature DB >> 24138645

Economic evaluations in European reimbursement submission guidelines: current status and comparisons.

Andrea Bracco1, Marieke Krol.   

Abstract

This study aimed to review European national health-economic (HE) guidelines and to identify recent developments in guideline recommendations by comparing the findings with those of a review published in 2001. Guidelines were identified by searching websites of the Internal Society for Pharmacoeconomics and Outcomes Research (ISPOR) and government health insurance agencies, and by a literature review. National guidelines showed broad consistency in ranking clinical data sources and choice of comparators for HE analysis, but varied in recommended costs to be included, methods related to cost calculation and discounting. Many European countries have developed or revised national HE guidelines. The recommendations in these guidelines differ in some key aspects, limiting transferability of outcomes of HE evaluations.

Mesh:

Year:  2013        PMID: 24138645     DOI: 10.1586/14737167.2013.837766

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  7 in total

Review 1.  Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries.

Authors:  Emelie Heintz; Andreas Gerber-Grote; Salah Ghabri; Francoise F Hamers; Valentina Prevolnik Rupel; Renata Slabe-Erker; Thomas Davidson
Journal:  Pharmacoeconomics       Date:  2016-01       Impact factor: 4.981

2.  Cost Effectiveness of the Use of Prophylactic Mesh To Prevent Parastomal Hernia After Urinary Diversion with an Ileal Conduit.

Authors:  Sanjib Saha; Ulf Gerdtham; Mats Bläckberg; Petter Kollberg; Fredrik Liedberg
Journal:  Eur Urol Open Sci       Date:  2022-04-21

3.  Update of the Dutch manual for costing studies in health care.

Authors:  Tim A Kanters; Clazien A M Bouwmans; Naomi van der Linden; Siok Swan Tan; Leona Hakkaart-van Roijen
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

Review 4.  Harmonization issues in unit costing of service use for multi-country, multi-sectoral health economic evaluations: a scoping review.

Authors:  Claudia Fischer; Susanne Mayer; Nataša Perić; Judit Simon
Journal:  Health Econ Rev       Date:  2022-08-03

Review 5.  Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples.

Authors:  Lan Gao; Hao Hu; Fei-Li Zhao; Shu-Chuen Li
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

6.  Health state utilities for metastatic breast cancer in Taiwan.

Authors:  Tzu-Chun Chou; Shao-Chin Chiang; Yu Ko
Journal:  Breast       Date:  2020-03-06       Impact factor: 4.380

7.  Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation.

Authors:  M Hiligsmann; J-Y Reginster; A N A Tosteson; S V Bukata; K G Saag; D T Gold; P Halbout; F Jiwa; E M Lewiecki; D Pinto; J D Adachi; N Al-Daghri; O Bruyère; M Chandran; C Cooper; N C Harvey; T A Einhorn; J A Kanis; D L Kendler; O D Messina; R Rizzoli; L Si; S Silverman
Journal:  Osteoporos Int       Date:  2018-10-31       Impact factor: 4.507

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.